Invasive Imaging of Bioresorbable Coronary Scaffolds - A Review

Login or register to view PDF.
Abstract

Various fully bioresorbable stents (BRS) have been recently developed, allowing for temporary scaffolding of the vessel wall. The potentially unique advantage of BRS to temporary scaffold the vessel could reduce the risk of adverse clinical outcomes caused by acute vessel geometry changes, late malapposition, jailed side branches or inflexibility of permanent stents. The design of BRS is, however, not similar for all stents, resulting in differences in degradation and behaviour. To assess the performance of BRS, the effect of degradation and behaviour on the vessel wall should be accurately evaluated. Intracoronary imaging techniques such as intravascular ultrasound (IVUS), optical coherence tomography (OCT) and near-infrared spectroscopy (NIRS) allow for detailed longitudinal evaluation of the stent and the vessel wall and might therefore aid in improving design and behaviour of BRS.

Disclosure
The authors have no conflicts of interest to declare.
Correspondence
Heleen MM van Beusekom, Department of Cardiology, Division of Experimental Cardiology, Ee2355a Erasmus University Medical Centre, Dr. Molewaterplein 50-60, 3015 GE Rotterdam, The Netherlands. E: h.vanbeusekom@erasmusmc.nl
Received date
20 March 2013
Accepted date
25 March 2013
Citation
Interventional Cardiology Review 2013;8(1):23–35
DOI
http://dx.doi.org/10.15420/icr.2013.8.1.23
References
  1. Grüntzig AR, Senning A, Siegenthaler WE, Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty, N Engl J Med, 1979;301(2):61–8.
    Crossref | PubMed
  2. Serruys PW, de Jaegere P, Kiemeneij F, et al., A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group, N Engl J Med, 1994;331(8):489–95.
    Crossref | PubMed
  3. Sousa JE, Costa MA, Abizaid A, et al., Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study, Circulation, 2001;103(2):192–5.
    Crossref | PubMed
  4. Sousa JE, Costa MA, Abizaid AC, et al., Sustained suppression of neointimal proliferation by sirolimus-eluting stents: oneyear angiographic and intravascular ultrasound follow-up, Circulation, 2001;104(17):2007–11.
    Crossref | PubMed
  5. Serruys PW, Garcia-Garcia HM, Onuma Y, From metallic cages to transient bioresorbable scaffolds: change in paradigm of coronary revascularization in the upcoming decade?, Eur Heart J, 2012;33(1):16–25b.
    Crossref | PubMed
  6. Colombo A, Karvouni E, Biodegradable stents : “fulfiling the mission and stepping away”, Circulation, 2000;102(4):371–3.
    Crossref | PubMed
  7. Gyongyosi M, Yang P, Hassan A, et al., Intravascular ultrasound predictors of major adverse cardiac events in patients with unstable angina, Clin Cardiol, 2000;23(7):507–15.
    Crossref | PubMed
  8. Forrest JK, Lansky AJ, Meller SM, et al., Evaluation of XIENCE V Everolimus-Eluting and Taxus Express2 Paclitaxel-Eluting Coronary Stents in Patients With Jailed Side Branches From the SPIRIT IV Trial at 2 Years, Am J Cardiol, 2013 [Epub ahead of print].
  9. Haude M, Erbel R, Erne P, et al., Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, fist-in-man BIOSOLVE-I trial, Lancet, 2013;381:836–44.
    Crossref | PubMed
  10. Okamura T, Onuma Y, García-García HM, et al., 3-Dimensional optical coherence tomography assessment of jailed side branches by bioresorbable vascular scaffolds: a proposal for classifiation, JACC Cardiovasc Interv, 2010;3(8):836–44.
    Crossref | PubMed
  11. Tamai H, Igaki K, Kyo E, et al., Initial and 6-Month Results of Biodegradable Poly-l-Lactic Acid Coronary Stents in Humans, Circulation, 2000;102(4):399–404.
    Crossref | PubMed
  12. Pollman MJ, Engineering a bioresorbable stent: REVA programme update, EuroIntervention, 2009;5 Suppl F:F54–7.
    Crossref | PubMed
  13. Scanlon PJ, Faxon DP, Audet AM, et al., ACC/AHA guidelines for coronary angiography: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Coronary Angiography) developed in collaboration with the Society for Cardiac Angiography and Interventions, Circulation, 1999;99(17):2345–57.
    Crossref | PubMed
  14. Sones FM Jr, Shirey EK, Cine coronary arteriography, Mod Concepts Cardiovasc Dis, 1962;31:735–8.
    PubMed
  15. Mintz GS, Nissen SE, Anderson WD, et al., American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents, J Am Coll Cardiol, 2001;37(5):1478–92.
    Crossref | PubMed
  16. Nair A, Kuban BD, Tuzcu EM, et al., Coronary plaque classifiation with intravascular ultrasound radiofrequency data analysis, Circulation, 2002;106(17):2200–6.
    Crossref | PubMed
  17. Rodriguez-Granillo GA, García-García HM, Mc Fadden EP, et al., In vivo intravascular ultrasound-derived thin-cap firoatheroma detection using ultrasound radiofrequency data analysis, J Am Coll Cardiol, 2005;46(11):2038–42.
    Crossref | PubMed
  18. Brugaletta S, Garcia-Garcia HM, Garg S, et al., Temporal changes of coronary artery plaque located behind the struts of the everolimus eluting bioresorbable vascular scaffold, Int J Cardiovasc Imaging, 2011;27(6):859–66.
    Crossref | PubMed
  19. Nishio S, Kosuga K, Igaki K, et al., Long-Term (>10 Years) clinical outcomes of fist-in-human biodegradable poly-llactic acid coronary stents: Igaki-Tamai stents, Circulation, 2012;125(19):2343–53.
    Crossref | PubMed
  20. Serruys PW, Ormiston JA, Onuma Y, et al., A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods, Lancet, 2009;373(9667):897–910.
    Crossref | PubMed
  21. Serruys P OY, on behalf of the ABSORB A and B investigators, editor. ABSORB Cohort B: 6M, 12M, 18M and 24M Follow-up. PCR BVS Focus group meeting; 8-9 March 2012; Rotterdam, The Netherlands.
  22. Bruining N, de Winter S, Roelandt JR, et al., Monitoring in vivo absorption of a drug-eluting bioabsorbable stent with intravascular ultrasound-derived parameters a feasibility study, JACC Cardiovasc Interv, 2010;3(4):449–56.
    Crossref | PubMed
  23. Gonzalo N, Serruys PW, Piazza N, Regar E, Optical coherence tomography (OCT) in secondary revascularisation: stent and graft assessment, EuroIntervention, 2009;5 Suppl D:D93–100.
    PubMed
  24. Okamura T, Garg S, Gutiérrez-Chico JL, et al., In vivo evaluation of stent strut distribution patterns in the bioabsorbable everolimus-eluting device: an OCT ad hoc analysis of the revision 1.0 and revision 1.1 stent design in the ABSORB clinical trial, EuroIntervention, 2010;5(8):932–8.
    Crossref | PubMed
  25. Yabushita H, Bouma BE, Houser SL, et al., Characterization of human atherosclerosis by optical coherence tomography, Circulation, 2002;106(13):1640–5.
    Crossref | PubMed
  26. Kubo T, Xu C, Wang Z, et al., Plaque and thrombus evaluation by optical coherence tomography, Int J Cardiovasc Imaging, 2011;27(2):289–98.
    Crossref | PubMed
  27. Ozaki Y, Okumura M, Ismail TF, et al., The fate of incomplete stent apposition with drug-eluting stents: an optical coherence tomography-based natural history study, Eur Heart J, 2010;31(12):1470–6.
    Crossref | PubMed
  28. Prati F, Regar E, Mintz GS, et al., Expert review document on methodology, terminology, and clinical applications of optical coherence tomography: physical principles, methodology of image acquisition, and clinical application for assessment of coronary arteries and atherosclerosis, Eur Heart J, 2010;31(4):401–15.
    Crossref | PubMed
  29. Prati F, Guagliumi G, Mintz GS, et al., Expert review document part 2: methodology, terminology and clinical applications of optical coherence tomography for the assessment of interventional procedures, Eur Heart J, 2012;33(20):2513–20.
    Crossref | PubMed
  30. Okamura T, Onuma Y, Garcia-Garcia HM, et al., First-in-man evaluation of intravascular optical frequency domain imaging (OFDI) of Terumo: a comparison with intravascular ultrasound and quantitative coronary angiography, EuroIntervention, 2011;6(9):1037–45.
    Crossref | PubMed
  31. Jamil Z, Tearney G, Bruining N, et al., Interstudy reproducibility of the second generation, Fourier domain optical coherence tomography in patients with coronary artery disease and comparison with intravascular ultrasound: a study applying automated contour detection, Int J Cardiovasc Imaging, 2013;29(1):39–51.
    Crossref | PubMed
  32. Onuma Y, Garg S, Okamura T, et al., Ten-year follow-up of the IGAKI-TAMAI stent. A posthumous tribute to the scientifi work of Dr. Hideo Tamai, EuroIntervention, 2009;5 Suppl F:F109–11.
    Crossref | PubMed
  33. Tanimoto S, Bruining N, van Domburg RT, et al., Late stent recoil of the bioabsorbable everolimus-eluting coronary stent and its relationship with plaque morphology, J Am Coll Cardiol, 2008;52(20):1616–20.
    Crossref | PubMed
  34. Karanasos A, Tu S, van der Linden M, et al., Online 3-dimensional rendering of optical coherence tomography images for the assessment of bifurcation intervention, Can J Cardiol, 2012;28(6):759.e1–3.
    Crossref | PubMed
  35. Gardner CM, Tan H, Hull EL, et al., Detection of lipid core coronary plaques in autopsy specimens with a novel catheter-based near-infrared spectroscopy system, JACC Cardiovasc Imaging, 2008;1(5):638–48.
    Crossref | PubMed
  36. Waxman S, Dixon SR, L’Allier P, et al., In vivo validation of a catheter-based near-infrared spectroscopy system for detection of lipid core coronary plaques: initial results of the SPECTACL study, JACC Cardiovasc Imaging, 2009;2(7):858–68.
    Crossref | PubMed
  37. Regar E, Invasive imaging technologies: can we reconcile light and sound?, J Cardiovasc Med (Hagerstown), 2011;12(8):562–70.
    Crossref | PubMed
  38. Garg S, Serruys PW, van der Ent M, et al., First use in patients of a combined near infra-red spectroscopy and intra-vascular ultrasound catheter to identify composition and structure of coronary plaque, EuroIntervention, 2010;5(6):755–6.
    Crossref | PubMed
  39. Schultz CJ, Serruys PW, van der Ent M, et al., First-in-man clinical use of combined near-infrared spectroscopy and intravascular ultrasound: a potential key to predict distal embolization and no-reflw?, J Am Coll Cardiol, 2010;56(4):314.
    Crossref | PubMed
  40. Wentzel JJ, van der Giessen AG, Garg S, et al., In vivo 3D distribution of lipid-core plaque in human coronary artery as assessed by fusion of near infrared spectroscopyintravascular ultrasound and multislice computed tomography scan, Circ Cardiovasc Imaging, 2010;3(6):e6–7.
    Crossref | PubMed
  41. Madder RD, Steinberg DH, Anderson RD, Multimodality direct coronary imaging with combined near-infrared spectroscopy and intravascular ultrasound: Initial US experience, Catheter Cardiovasc Interv, 2013;81(3):551–7.
    Crossref | PubMed
  42. Goldstein JA, Maini B, Dixon SR, et al., Detection of lipidcore plaques by intracoronary near-infrared spectroscopy identifis high risk of periprocedural myocardial infarction, Circ Cardiovasc Interv, 2011;4(5):429–37.
    Crossref | PubMed
  43. Diletti R, Serruys PW, Farooq V, et al., ABSORB II randomized controlled trial: A clinical evaluation to compare the safety, effiacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: Rationale and study design, Am Heart J, 2012;164(5):654–63.
    Crossref | PubMed
  44. Stack RS, Califf RM, Phillips HR, et al., Interventional cardiac catheterization at Duke Medical Center, Am J Cardiol, 1988;62(10 Pt 2):3F–24F.
    Crossref | PubMed
  45. Heublein B, Rohde R, Kaese V, et al., Biocorrosion of magnesium alloys: a new principle in cardiovascular implant technology?, Heart, 2003;89(6):651–6.
    Crossref | PubMed
  46. Erbel R, Di Mario C, Bartunek J, et al., Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial, Lancet, 2007;369(9576):1869–75.
    Crossref | PubMed
  47. Waksman R, Erbel R, Di Mario C, et al., Early- and long-term intravascular ultrasound and angiographic fidings after bioabsorbable magnesium stent implantation in human coronary arteries, JACC Cardiovasc Interv, 2009;2(4):312–20.
    Crossref | PubMed
  48. Waksman R, Lessons learned from preclinical studies of magnesium scaffolds (Biotronik’s DREAMS program), Presented at: PCR focus group on bioresorbable vascular scaffolds, Rotterdam, The Netherlands, 8-9 March 2012.
  49. Haude M, Erbel R, Verheye S, et al., Twelve-month safety and performance results of the paclitaxel-eluting bioabsorbable magnesium scaffold in the prospective, multicenter fist-inman trial - BIOSOLVE-I, Presented at: European Society of Cardiology Congress, Munich, Germany, 25-29 August 2012.
  50. Haude M, Erbel R, Erne P, et al., Two-year clinical data of cohort 1 and multi-modality imaging results up to 1 year follow-up of the BIOSOLVE-I study with the paclitaxel-eluting bioabsorbable magnesium scaffold (DREAMS), Presented at: Transcatheter Cardiovascular Therapeutics, Miami, US, 22-25 October 2012.
  51. Koolen J, Erbel R, Verheye S, et al., Intravascular ultrasound results with the drug eluting absorbable metal scaffold in the BIOSOLVE-I study up to twelve months follow-up, Presented at: European Society of Cardiology Congress, Munich, Germany, 27 August 2012.
  52. Haude M, Biotronik: from PROGRESS to DREAMS, Presented at: PCR Focusgroup, Rotterdam, The Netherlands, 7-8 March 2013.
  53. Ormiston JA, Serruys PW, Regar E, et al., A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial, Lancet, 2008;371(9616):899–907.
    Crossref | PubMed
  54. Karanasos A, Simsek C, Serruys P, et al., Five-year optical coherence tomography follow-up of an everolimus-eluting bioresorbable vascular scaffold: changing the paradigm of coronary stenting?, Circulation, 2012;126(7):e89–91.
    Crossref | PubMed
  55. Onuma Y, Nieman K, Webster M, et al., Five-year clinical outcomes and non-invasive angiographic imaging results with functional assessment after bioresorbable everolimus-eluting scaffold implantation in patients with de novo coronary artery disease, Presented at: Transcatheter Cardiovascular Therapeutics, Miami, US, 22-26 October 2012.
  56. García-García HM, Schultz C, Duckers E, et al., Five-year follow-up of the ABSORB bioresorbable everolimus-eluting vascular scaffold system: multimodality imaging assessment, EuroIntervention, 2013;8(10):1126–7.
    Crossref | PubMed
  57. Serruys PW, Onuma Y, Ormiston JA, et al., Evaluation of the second generation of a bioresorbable everolimus drugeluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes, Circulation, 2010;122(22):2301–12.
    Crossref | PubMed
  58. Serruys PW, Onuma Y, Dudek D, et al., Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes, J Am Coll Cardiol, 2011;58(15):1578–88.
    Crossref | PubMed
  59. Van Geuns RJ, Preliminary data from ABSORB EXTEND: a report of the 6-month clinical outcomes from the fist 269 patients registered, Presented at: EuroPCR, Paris, France, 15-18 May 2012.
  60. Diletti R, Why do we use IVUS-VH 45MHz and Lipiscan in the ABSORB II trial?, Presented at: PCR BVS Focus group meeting, Rotterdam, The Netherlands, 8-9 March 2012.
  61. Stone GW, ABSORB III and IV: pivotal clinical trial program, Transcatheter Cardiovascular Therapeutics, Miami, US, 22-26 October 2012.
  62. Kaluza G, The REVA Tyrosine-Derived Polycarbonate Bioresorbable Scaffold: Long-term Outcomes Using Multimodality Imaging, Presented at: Transcatheter Cardiovascular Therapeutics, San Francisco, CA, US 7-11 November 2011.
  63. Grube E, Bioabsorbable stents: the Boston Scientifi & REVA technology, Presented at: EuroPCR, Barcelona, Spain, 19-22 May 2009.
  64. Abizaid A, REVA: Clinical update and case presentation, Presented at: PCR BVS Focus group meeting, Rotterdam, The Netherlands, 6-9 March 2012.
  65. Abizaid A, ReZolve Clinical Program Update, Presented at: PCR Focusgroup, Rotterdam, The Netherlands, 7-8 March 2013.
  66. Jabara R, Pendyala L, Geva S, et al., Novel fully bioabsorbable salicylate-based sirolimus-eluting stent, EuroIntervention, 2009;5 Suppl F:F58–64.
    Crossref | PubMed
  67. Jabara C, Matsumoto, Bio-mechanical properties and ABC of bioresorption of adipic acid, Presented at: PCR BVS Focus group meeting, Rotterdam, The Netherlands, 8-9 March 2012.
  68. Verheye S, DESolve First In Man Study: Preliminary results, Presented at: PCR BVS Focus group meeting, Rotterdam, The Netherlands, 8-9 March 2012.
  69. Verheye S, Elixir Technology, Presented at: EuroPCR, Paris, France, 15-18 May 2012.
  70. Verheye S, Multicenter First-in-Man evaluation of the myolimus-eluting bioresorbable coronary scaffold: 6 month imaging and 12-month clinical results, TCT 2012, Miami & Verheye S, First-in-man results with a myolimus-eluting bioresorbable PLLA-based vascular scaffold (Elixir DESolve), Presented at: Transcatheter Cardiovascular Therapeutics, Miami, US, 22-26 October 2012.
  71. Lafont, ART bioresorbable scaffold dedicated for vascular scaffolding, Presented at: EuroPCR, Paris, France, 15-18 May 2012.
  72. Lafont A, Sizing does not matter: ART concept, Presented at: EuroPCR, Paris, France, 15-18 May 2012.
  73. ART. ART news, 2012; Available at: www.art-stent.com/news (accessed 26 March 2013).
  74. Fajadet J, Bioresorbable vascular scaffolds: latest designs and clinical study evidence, The ART stent: design and early fist-in-man experiences, Presented at: Transcatheter Cardiovascular Therapeutics, Miami, US, 22-26 October 2012.
  75. Shen L, Wang Q, Wu Y, et al., Short-term effects of fully bioabsorbable PLLA coronary stents in a porcine model, Polymer Bulletin, 2012;68:1171–81.
    Crossref
  76. Cottone RJ, Structural lessons learned: blended PLLA scaffold partitioned coating with abluminal sirolimus drug elution matrix and luminal +CD34 antibody for EPC capture, Presented at: PCR BVS Focus group meeting, Rotterdam, The Netherlands, 8-9 March 2012.
  77. Cottone RJ, Blended PLLA scaffold partitioned coating with abluminal sirolimus drug elution matrix and luminal +CD34 antibody for EPC capture, Presented at: EuroPCR, Paris, France, 15-18 May 2012.
  78. Cottone RJ, Blended PLLA scaffold with partitioned coating of abluminal sirolimus drug elution matrix and luminal antihCD34 antibody for EPC capture, Presented at: Transcatheter Cardiovascular Therapeutics, Miami, US, 22-26 October 2012.
  79. Iqbal J, Amaranth Bioresorbable Scaffold - pre-clinical data, Presented at: PCR Focusgroup, Rotterdam, The Netherlands, 7-8 March 2013.
  80. Naber CK, Leapfrogging to bioresorbable scaffolds: update on MeRes, Presented at: Transcatheter Cardiovascular Therapeutics, Miami, US, 24 October 2012.
  81. Wu C, A preliminary study of biodegradable n stent in mini-swine coronary artery, Presented at: Transcatheter Cardiovascular Therapeutics, Miami, US, 22-26 October 2012.
  82. Gutiérrez-Chico JL, Serruys PW, Girasis C, et al., Quantitative multi-modality imaging analysis of a fully bioresorbable stent: a head-to-head comparison between QCA, IVUS and OCT, Int J Cardiovasc Imaging, 2012;28(3):467–78.
    Crossref | PubMed
  83. Tu S, Holm NR, Koning G, et al., Fusion of 3D QCA and IVUS/ OCT, Int J Cardiovasc Imaging, 2011;27(2):197–207.
    Crossref | PubMed
  84. Tu S, Xu L, Ligthart J, et al., In vivo comparison of arterial lumen dimensions assessed by co-registered threedimensional (3D) quantitative coronary angiography, intravascular ultrasound and optical coherence tomography, Int J Cardiovasc Imaging, 2012;28(6):1315–27.
    Crossref | PubMed
  85. van Ditzhuijzen NS, van den Heuvel M, Sorop O, et al., Invasive coronary imaging in animal models of atherosclerosis, Neth Heart J, 2011;19(10):442–6.
    Crossref | PubMed